Bachem Holding AG

BANB

CH1176493729

Biotechnology & Medical Research

Market Closed - Swiss Exchange Other stock markets 11:31:51 2024-04-24 am EDT			5-day change	1st Jan Change
80.95 ^CHF	-0.25%		+0.81%	+24.54%

Mar. 07	Switzerland's Bachem Reports Improved FY23 Net Income, Sales	MT
Mar. 07	Transcript : Bachem Holding AG, 2023 Earnings Call, Mar 07, 2024

Bachem Holding AG(SWX:001253020) dropped from Swiss Performance Index (Price Return)

May 16, 2022 at 12:00 am EDT

Bachem Holding AG has been removed from Swiss Performance Index (Price Return) .

Latest news about Bachem Holding AG

Switzerland's Bachem Reports Improved FY23 Net Income, Sales	Mar. 07	MT
Transcript : Bachem Holding AG, 2023 Earnings Call, Mar 07, 2024	Mar. 07
Bachem Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 25	CI
Transcript : Bachem Holding AG - Special Call	Jan. 31
Sandoz Spin-off Prompts Swiss Extraordinary Index Changes in October	23-09-25	MT
Bachem CEO Assumes Operations Chief Role Amid Executive Committee Shakeup	23-09-15	MT
Transcript : Bachem Holding AG, H1 2023 Earnings Call, Jul 27, 2023	23-07-27
Bachem Posts Lower H1 Net Income; Sales Up	23-07-27	MT
Bachem Holding AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-26	CI
Charts in perspective	23-07-07
Is the Fed's message bizarre?	23-06-15
Certain Shares of Bachem Holding AG are subject to a Lock-Up Agreement Ending on 8-JUN-2023.	23-06-07	CI
Global markets live: EssilorLuxottica, AT&T, Tesla, Credit Suisse, Sony...	23-04-21
Bank Vontobel Lifts Price Target on Bachem, Maintains Hold Recommendation	23-03-10	MT
Bachem Raises CHF108 Million to Expand Capacity at Swiss Sites	23-03-10	MT
Bachem Plans Capital Raising to Expand Capacity at Swiss Sites	23-03-10	MT
Bachem Posts Lower FY22 Attributable Net Income	23-03-07	MT
Bachem Holding AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-06	CI
Bachem Wins CHF500 Million Order for Peptides Supply Until 2031	23-03-03	MT
Credit Suisse Lifts Price Target Bachem, Maintains Outperform Recommendation	22-12-16	MT
Swiss Biotech Bachem Secures CHF1 Billion Contract to Deliver Peptides for Five Years	22-12-16	MT
Octavian Lifts Price Target on Bachem, Maintains Buy Recommendation	22-12-12	MT
European shares retreat amid interest rate jitters, recession fears	22-10-05	RE
Biotechnology Group Bachem To Buy New Site In Switzerland	22-10-05	MT
Global markets live: Apple, United Health, Ford, PepsiCo, Peloton...	22-09-20

Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.

Sector

Biotechnology & Medical Research

Calendar

2024-04-25 - Ex-dividend day for final dividend

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Ratings for Bachem Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

80.95 CHF

Average target price

70.8 CHF

Spread / Average Target

-12.54%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BACHEM HOLDING AG	+24.54%	6.64B
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+47.81%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research